Skip to search formSkip to main contentSkip to account menu

apaziquone

Known as: 1H-Indole-4,7-dione, 5-(1-aziridinyl)-3-(hydroxymethyl)-2- ((1E)-3-hydroxy-1-propenyl)-1-methyl-, 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol, 3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione)prop-beta-en-alpha-ol 
An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (3)

Antineoplastic AgentsAziridinesIndolequinones

Narrower (4)

E09EO 9EoquinNSC 382,459
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The pharmacological evaluation and development of novel anti-cancer compounds
The work presented in this thesis represents my ‘adventures’ in the field of cancer pharmacology and drug development. The work… 
2012
2012
Intravesical apaziquone injection after transurethral resection for cancer treatment
FIELD: medicine. SUBSTANCE: for bladder cancer treatment, effective amounts of apaziquone are administered intravesically… 
2012
2012
Abstract 5462: Single dose dermal irritation study of apaziquone in rabbits
Introduction and Objectives: Apaziquone is a novel bioreductive alkylating agent in development for intravesical therapy of… 
2010
2010
The efficacy of varying concentrations of intravesical apaziquone on murine bladder cancer in an animal model.
e15101 Background: This preclinical study compared the efficacy of varying concentrations of apaziquone, an intravesical… 
Review
2009
Review
2009
FDA Pipeline preview, September 2009 (cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, beclomethasone 17,21-dipropionate)
Recent FDA action (through September 2009) related to cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, and… 
2009
2009
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer Hendricksen,
Objectives To study the time-to-recurrence and duration of response in non-muscle invasive bladder cancer (NMIBC) patients, with… 
Review
2008
Review
2008
Apaziquone for non-muscle invasive bladder cancer: a critical review
Objective: To describe clinical needs in non-muscle invasive bladder cancer (NMIBC) and review the potential of apaziquone in… 
2008
2008
Introduction of apaziquone intravesical after transurethral resection in cancer treatment
FIELD: medicine. SUBSTANCE: group of inventions relates to medicine and are intended for treating urinary bladder cancer… 
2008
2008
Intravesical apaziquone administration following transurethral resection for treating cancer
Bladder cancer treatments include the intravesical administration of apaziquone immediately (e.g. within about 6 hours) following… 
2008
2008
Intravesical apaziquone administration of transurethral resection for treating cancer
Bladder cancer treatments include the intravesical administration of apaziquone immediately (e.g. within about 6 hours) following…